Cases & Deals

Cellectis completes $164 million follow-on public offering of American Depositary Shares on NASDAQ

Clients Cellectis SA

Jones Day represented Cellectis S.A., a French clinical-stage biopharmaceutical developer of innovative cancer treatments using gene editing technologies, in connection with a $164 million public offering of American Depositary Shares on NASDAQ, underwritten by Goldman Sachs & Co. LLC, Citigroup, and Barclays.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.